Benjamin A. Katchman Joins Cannabis Science and Technology’s Editorial Advisory Board

Cannabis Science and Technology is pleased to announce the addition of Benjamin A. Katchman, PhD, to its editorial advisory board (EAB).

Dr. Katchman received a B.S. in microbiology from Indiana University in 2005, then carried out graduate research with Professor Douglas F. Lake at Arizona State University where he was the first to identify QSOX1 as a proto-oncogene and novel tumor biomarker resulting in more than $2M in funding and multiple patents. Katchman performed his postdoctoral research with Professors Karen S. Anderson and Joshua LaBaer where he designed novel high-density protein microarrays and novel clinical and point of care diagnostics utilizing flexible organic light-emitting diode (OLED)-based electronics resulting in more than $15M in funding, multiple patents, and high-impact publications.

Dr. Katchman is a Principal Scientist at PathogenDx where he leads the research and development of sample preparation and assay development. PathogenDx is a Scottsdale, Arizona based company that provides disruptive DNA-based pathogen testing technology and solutions for the cannabis, botanical, food, and agricultural industries.

Previously, Dr. Katchman spent 20 years working with various universities and small companies developing novel nucleic acid and proteomic approaches for biomarker discovery and molecular diagnostics. This includes the development of plate-based and microarray-based diagnostic systems for use in clinical laboratories and point-of-care diagnostics for Arizona State University, FlexBioTech, Inc., and Eccrine Systems, Inc.

Prior to joining PathogenDx, Dr. Katchman was a Principle Investigator at Eccrine Systems, Inc., where he led all clinical research, regulatory pathway implementation, assay development, and biomarker studies. He was the co-founder of FlexBioTech, Inc., where he led the development of novel OLED-based molecular diagnostic assay platforms.